Search results
Showing 121 to 135 of 147 results for sclerosis
Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)
Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.
This advice has been updated and replaced by NICE guideline NG220.
This guidance has been updated and replaced by NICE guideline NG220.
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Discontinued Reference number: GID-TA11357
Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)
This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]
In development Reference number: GID-TA11762 Expected publication date: 28 July 2025
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)
This guidance has been updated and replaced by NICE technology appraisal guidance 616.
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
We have moved interventional procedures guidance 640 to become HealthTech guidance 501. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE interventional procedures guidance 640.
In development Reference number: GID-TA11352 Expected publication date: TBC
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.